Here’s What Hit Humana (HUM) in Q1
Key takeaways
- The equity market faced challenges in the first quarter due to the Iran conflict and the related energy price hike, compounded by continued AI-related uncertainty.
- In its first-quarter 2026 investor letter, Pzena Focused Value Strategy highlighted Humana Inc.
- Pzena Focused Value Strategy stated the following regarding Humana Inc.
Here’s What Hit Humana (HUM) in Q1 Soumya Eswaran Tue, June 23, 2026 at 8:10 PM GMT+7 2 min read HUM Pzena Investment Management recently released its first-quarter 2026 commentary for “Pzena Focused Value Strategy.” A copy of the letter can be downloaded here. The equity market faced challenges in the first quarter due to the Iran conflict and the related energy price hike, compounded by continued AI-related uncertainty. Despite this volatility, energy stocks led the value index higher, but the portfolio fell short of the index and returned -4.7% (net) vs. 2.1% for the Russell 1000 Value Index. Despite the uncertainty, the firm believes that the current environment presents a strong long-term opportunity. In addition, you can check the Fund’s top five holdings to see its best picks for 2026.
In its first-quarter 2026 investor letter, Pzena Focused Value Strategy highlighted Humana Inc. (NYSE:HUM). Humana Inc. (NYSE:HUM) is an American insurance company that provides medical and specialty insurance products. On June 22, 2026, Humana Inc. (NYSE:HUM) closed at $360.72 per share. One-month return of Humana Inc. (NYSE:HUM) was 19.57%, and its shares gained 51.06% over the past 52 weeks. Humana Inc. (NYSE:HUM) has a market capitalization of $43.31 billion.
Pzena Focused Value Strategy stated the following regarding Humana Inc. (NYSE:HUM) in its Q1 2026 investor letter: